Kalil Jennifer, Bowes Jennifer, Reddy Deepti, Barrowman Nick, Le Saux Nicole
Department of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Canada.
Children's Hospital of Eastern Ontario Research Institute, Ottawa, Canada.
Pediatr Qual Saf. 2019 Aug 30;4(5):e211. doi: 10.1097/pq9.0000000000000211. eCollection 2019 Sep-Oct.
Bronchiolitis is a common lower respiratory tract illness in young children often caused by the respiratory syncytial virus (RSV). Antimicrobials are not recommended in infants with bronchiolitis unless there is strong evidence that a bacterial coinfection exists.
We conducted a retrospective chart review comparing antimicrobial use and outcomes in previously healthy infants ≤24 months of age with RSV bronchiolitis at a single Canadian tertiary pediatric hospital during RSV seasons (December-April) from 2011 to 2016. An audit and feedback antimicrobial stewardship program was introduced in this hospital in August 2014.
Compared with the 2011-2012 cohort, the 2015-2016 cohort showed a decrease of 46% in mean days of therapy per 1,000 patient-days in the >28 days old age group of patients. There was also a 15.1% absolute reduction in the proportion of patients who received any antimicrobials in the hospital between the 2 cohorts (neonates included). The proportion of patients receiving antimicrobial prescriptions at discharge also decreased from 33.5% to 19%. The use of second-generation cephalosporins was eliminated in the 2016 cohort. There was a significant decrease in length of stay between the 2011-2012 and 2015-2016 cohorts, and no readmissions were documented.
This study adds to the accumulating literature that antimicrobial stewardship program interventions along with guidelines and order sets can safely contribute to a reduction in antimicrobial use both in hospital and at discharge in children <2 years of age hospitalized due to RSV. Further research in identifying those who would or would not benefit from antibiotics should be promoted.
细支气管炎是幼儿常见的下呼吸道疾病,通常由呼吸道合胞病毒(RSV)引起。除非有强有力的证据表明存在细菌合并感染,否则不建议对患细支气管炎的婴儿使用抗菌药物。
我们进行了一项回顾性病历审查,比较了2011年至2016年呼吸道合胞病毒流行季节(12月至4月)期间,加拿大一家三级儿科医院中年龄≤24个月、此前健康的RSV细支气管炎婴儿的抗菌药物使用情况和治疗结果。2014年8月,该医院引入了一项审核与反馈抗菌药物管理计划。
与2011 - 2012队列相比,2015 - 2016队列中年龄>28天的患者每1000患者日的平均治疗天数减少了46%。在这两个队列(包括新生儿)中,住院期间接受任何抗菌药物治疗的患者比例绝对下降了15.1%。出院时接受抗菌药物处方的患者比例也从33.5%降至19%。2016队列中不再使用第二代头孢菌素。2011 - 2012队列和2015 - 2016队列之间的住院时间显著缩短,且无再入院记录。
本研究进一步补充了现有文献,表明抗菌药物管理计划干预措施以及指南和医嘱集可安全地减少因RSV住院的2岁以下儿童在医院和出院时的抗菌药物使用。应推动进一步研究,以确定哪些人会或不会从抗生素治疗中受益。